Literature DB >> 20045292

Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole.

Ching-Lan Lu, Chia-Ying Liu, Chun-Hsing Liao, Yu-Tsung Huang, Hsiu-Po Wang, Po-Ren Hsueh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20045292     DOI： 10.1016/j.ijantimicag.2009.11.008

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN： 0924-8579            Impact factor:   5.283


× No keyword cloud information.
  20 in total

1.  Tigecycline suppresses toxin A and B production and sporulation in Clostridium difficile.

Authors:  Michael John Aldape; Dustin Delaney Heeney; Amy Evelyn Bryant; Dennis Leroy Stevens
Journal:  J Antimicrob Chemother       Date:  2014-08-23       Impact factor: 5.790

Review 2.  Recurrent Clostridium difficile infection: From colonization to cure.

Authors:  Kelsey Shields; Roger V Araujo-Castillo; Thimmaiah G Theethira; Carolyn D Alonso; Ciaran P Kelly
Journal:  Anaerobe       Date:  2015-04-27       Impact factor: 3.331

Review 3.  Treatment of refractory and recurrent Clostridium difficile infection.

Authors:  Christina M Surawicz; Jacob Alexander
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04-19       Impact factor: 46.802

Review 4.  Recurrent Clostridium difficile infection: what are the treatment options?

Authors:  Claire M F van Nispen tot Pannerden; Annelies Verbon; Ernst J Kuipers
Journal:  Drugs       Date:  2011-05-07       Impact factor: 9.546

Review 5.  The potential for emerging therapeutic options for Clostridium difficile infection.

Authors:  Harsh Mathur; Mary C Rea; Paul D Cotter; R Paul Ross; Colin Hill
Journal:  Gut Microbes       Date:  2014

6.  Severe anaphylaxis caused by orally administered vancomycin to a patient with Clostridium difficile infection.

Authors:  D Bossé; C Lemire; J Ruel; A M Cantin; F Ménard; L Valiquette
Journal:  Infection       Date:  2012-09-21       Impact factor: 3.553

7.  Antimicrobial susceptibilities and molecular epidemiology of clinical isolates of Clostridium difficile in taiwan.

Authors:  Yi-Chun Lin; Yu-Tsung Huang; Pei-Jane Tsai; Tai-Fen Lee; Nan-Yao Lee; Chun-Hsing Liao; Shyr-Yi Lin; Wen-Chien Ko; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

8.  Effects of tigecycline and vancomycin administration on established Clostridium difficile infection.

Authors:  Casey M Theriot; Cassie A Schumacher; Christine M Bassis; Anna M Seekatz; Vincent B Young
Journal:  Antimicrob Agents Chemother       Date:  2014-12-29       Impact factor: 5.191

9.  Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection.

Authors:  Christine M Bassis; Casey M Theriot; Vincent B Young
Journal:  Antimicrob Agents Chemother       Date:  2014-03-03       Impact factor: 5.191

10.  Clostridium butyricum enhances colonization resistance against Clostridioides difficile by metabolic and immune modulation.

Authors:  Mao Hagihara; Tadashi Ariyoshi; Yasutoshi Kuroki; Shuhei Eguchi; Seiya Higashi; Takeshi Mori; Tsunemasa Nonogaki; Kenta Iwasaki; Makoto Yamashita; Nobuhiro Asai; Yusuke Koizumi; Kentaro Oka; Motomichi Takahashi; Yuka Yamagishi; Hiroshige Mikamo
Journal:  Sci Rep       Date:  2021-07-22       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.